symbol,price,beta,volAvg,mktCap,lastDiv,range,changes,companyName,currency,cik,isin,cusip,exchange,exchangeShortName,industry,website,description,ceo,sector,country,fullTimeEmployees,phone,address,city,state,zip,dcfDiff,dcf,image,ipoDate,defaultImage,isEtf,isActivelyTrading,isAdr,isFund
ICPT,18.62,0.89319,1908817,778468684,0,8.82-21.86,-0.04,"Intercept Pharmaceuticals, Inc.",USD,0001270073,US45845P1084,45845P108,NASDAQ Global Select,NASDAQ,Biotechnology,https://www.interceptpharma.com,"Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults. It is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis; and other product candidates in various stages of clinical and preclinical development. The company has a license agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United States. It markets its products through an internal commercial organization and third-party distributors. The company was incorporated in 2002 and is headquartered in New York, New York.",Mr. Jerome B. Durso,Healthcare,US,341,646 747 1000,10 Hudson Yards,New York,NY,10001,0.880823,17.5192,https://financialmodelingprep.com/image-stock/ICPT.png,2012-10-11,False,False,True,False,False
